Expert Ratings For Viridian Therapeutics
Portfolio Pulse from Benzinga Insights
In the last three months, 7 analysts have published ratings on Viridian Therapeutics (NASDAQ: VRDN), with the majority being bullish. The average 12-month price target has dropped by 12.88% to $26.86. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance.
July 16, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Viridian Therapeutics has received mostly bullish ratings from analysts, but the average 12-month price target has decreased by 12.88% to $26.86. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance.
The majority of analysts are bullish on VRDN, but the decrease in the average price target suggests tempered expectations. This mixed sentiment may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100